Latham & Watkins Advises Innocoll Biotherapeutics in US$125 Million Term Loan with Leading Biotech Investor Oaktree Capital

Firm represents the international specialty pharmaceutical company in a growth financing transaction.

February 01, 2022

Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, has announced the successful closing of a new US$125 million term loan provided by funds managed by Oaktree Capital Management, L.P.

Latham & Watkins LLP represents Innocoll Biotherapeutics with a transactional team led by California finance partners Haim Zaltzman and Elizabeth Oh, with associates Hyunji Lee and Dong Whi (Tony) Noh. Advice has also been provided on corporate matters by California partner Ben Potter and Boston associate Erik Thompson; on intellectual property matters by California partners Judith Hasko and Jekkie Kim; on ERISA matters by California partner Julie Crisp; on regulatory matters by California counsel Betty Pang and Washington, D.C. associate Chad Jennings; on tax matters by California partner Katharine Moir and associate Alexander Farris; and on German legal matters by Frankfurt partner Torsten Volkholz and associate Anna-Maria Kuckerz.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.